As of November 6, 2026, Pyxis Oncology, Inc. is a publicly traded company (Nasdaq: PYXS); its largest reported holder is GordonMD Global Investments LP, with 16.4% on Schedule 13G/A of October 9, 2026, then BVF Partners (9.99%) (Schedule 13G/A, October 9, 2026).
Is this your company?
About to sign with, pay or invest in Pyxis Oncology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Pyxis Oncology, Inc. a real, registered company?
- Pyxis Oncology, Inc. files with the SEC under CIK 1782223 (its SEC filings).
- Its shares are listed under the ticker PYXS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Pyxis Oncology, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Thomas Civik, Chief Executive Officer (Form 8-K filed 2026-09-08). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Laurion Capital Management LP (filed 2026-11-03).
Who are Pyxis Oncology, Inc.'s owners and officers?
Pyxis Oncology, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-03 | Laurion Capital Management LP | 5.16% |
| Schedule 13G/A, 2026-10-09 | Gordonmd Global Investments LP | 16.4% |
| Schedule 13G, 2026-10-05 | Coastlands Capital LP | 5.42% |
| Schedule 13G/A, 2026-10-02 | Gordonmd Global Investments LP | 17.5% |
| Schedule 13G, 2026-07-10 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2026-07-02 | Gordonmd Global Investments LP | 12.1% |
| Schedule 13G/A, 2026-02-09 | Laurion Capital Management LP | 7.72% |
| Schedule 13G/A, 2025-10-14 | Millennium Management LLC | 1.3% |
| Schedule 13G, 2025-09-23 | Gordonmd Global Investments LP | 6.2% |
| Schedule 13G/A, 2025-07-17 | Blackrock, Inc. | 1.5% |
| Schedule 13G, 2025-07-01 | Millennium Management LLC | 5.7% |
Questions about who owns Pyxis Oncology, Inc.
Who owns Pyxis Oncology, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Pyxis Oncology, Inc.: Gordonmd Global Investments LP (16.4%, Schedule 13G/A, filed 2026-10-09), Bvf Partners L P/Il (9.99%, Schedule 13G, filed 2026-07-10), Coastlands Capital LP (5.42%, Schedule 13G, filed 2026-10-05) and Laurion Capital Management LP (5.16%, Schedule 13G/A, filed 2026-11-03).
Who are the largest shareholders of Pyxis Oncology, Inc.?
By the share each holder's latest filing reports, the largest holders of Pyxis Oncology, Inc. on this page are Gordonmd Global Investments LP (16.4%), Bvf Partners L P/Il (9.99%) and Coastlands Capital LP (5.42%).
When did Gordonmd Global Investments LP buy into Pyxis Oncology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Gordonmd Global Investments LP on this page is the Schedule 13G, filed 2025-09-23, reporting 6.2%; its latest, Schedule 13G/A filed 2026-10-09, reports 16.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Pyxis Oncology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Pyxis Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pyxis Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-08 | Thomas Civik | Chief Executive Officer | appointed | |
| Form 8-K, 2026-09-08 | Thomas Civik | Chairman of the Board | appointed | 2026-09-04 |
| Form 8-K, 2026-09-08 | Santhosh Palani | departed | 2026-09-04 |
Which insiders own Pyxis Oncology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 15,541,909 shares (13.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-02).
- GordonMD Global Investments LP, a 10% owner: 15,541,909 shares (13.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-02).
- GordonMD Long Biased Master Fund LP, a 10% owner: 15,541,909 shares (13.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-02).
- GordonMD Long Biased GP LLC, a 10% owner: 15,541,909 shares (13.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-02).
- , the chief operating officer and chief financial officer: 2,314,886 shares (1.9% of shares outstanding), held indirectly through a trust (Form 4, 2024-11-27).
Shares outstanding: 119,607,855 as of 2026-11-04, from the company's latest SEC cover page.
How much has Pyxis Oncology, Inc. raised?
No fundraising or offering filing from Pyxis Oncology, Inc. is on file with us.
Keep reading
More on Pyxis Oncology, Inc. and the records around it.
Pyxis Oncology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- GordonMD Global Investments LP also filed stake reports on 1 other company: Kyverna Therapeutics, Inc. (Nov 2025)
- Laurion Capital Management LP also filed stake reports on 2 other companies: IMMUNIC, INC. (Aug 2026), Rallybio Corp (Aug 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/pyxis-oncology